aTYR PHARMA ATYR
NASDAQ ATYR
$0.38 +0.01 (+4.13%)
As of: Sep 21, 2026 · 10:48 AM EDT

aTYR PHARMA (ATYR) Long-Term Investments (2015 - 2016)

aTYR PHARMA's (ATYR) quarterly Long-Term Investments came in at $4.0 million in Q4 2016, down 86.58% on a YoY basis from $29.8 million in Q1 2016, and down 61.25% quarter-over-quarter from $10.3 million in Q3 2016.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

aTYR PHARMA (ATYR) Long-Term Investments (2015 - 2016) Analysis & Trends

aTYR PHARMA (ATYR) has reported Long-Term Investments for 2 consecutive years, with $4.0 million the latest figure, recorded in Q4 2016.

  • For the quarter ending Q4 2016, Long-Term Investments fell 86.58% year-over-year to $4.0 million; the trailing twelve-month figure through Dec 2016 stood at $4.0 million (down 86.58% YoY), and the FY2016 full-year result was $4.0 million, down 86.58% from the prior year.
  • Long-Term Investments eased to $4.0 million in Q4 2016 per ATYR's latest filing, from $10.3 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $44.7 million in Q2 2015 and bottomed at $4.0 million in Q4 2016.
Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Amgen 208.48 Bn 194.49 Bn 7.24 Bn -
2 Gilead Sciences 186.29 Bn 183.02 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 128.79 Bn 120.93 Bn 2.84 Bn 5.79 Bn
4 Regeneron Pharmaceuticals 80.66 Bn 72.67 Bn 3.93 Bn 9.83 Bn
5 Moderna 61.46 Bn 56.32 Bn 52.00 Mn 1.77 Bn
6 Argenx Se 61.28 Bn 56.10 Bn 1.37 Bn -4.00 Mn
7 Alnylam Pharmaceuticals 32.04 Bn 28.73 Bn 992.69 Mn 22.17 Mn
8 Biogen 31.84 Bn 30.56 Bn 1.96 Bn -
9 Roivant Sciences 28.74 Bn 29.43 Bn 1.16 Mn -
10 aTYR PHARMA 35.31 Mn -22.30 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2016 4.00 Mn
Sep 30, 2016 10.33 Mn
Jun 30, 2016 12.66 Mn
Mar 31, 2016 25.56 Mn
Dec 31, 2015 29.81 Mn
Sep 30, 2015 28.01 Mn
Jun 30, 2015 44.74 Mn